Company Overview

IGC Pharma, Inc. is a U.S.-based biotechnology and pharmaceutical development company focused primarily on neurodegenerative diseases, particularly Alzheimer’s disease, as well as related areas involving cognitive impairment and chronic conditions. The company operates within the biotechnology, pharmaceutical research, and clinical-stage drug development industries. Its principal activities involve developing cannabinoid-based therapeutic candidates and artificial intelligence-supported clinical research tools intended to address neurological and metabolic disorders. Public filings and investor materials identify Alzheimer’s disease therapeutics as the company’s primary strategic focus.

The company’s core revenue historically included legacy infrastructure and product activities through subsidiaries, but in recent years its strategic emphasis has shifted toward pharmaceutical research and clinical development. IGC Pharma’s lead drug candidate, IGC-AD1, is being evaluated for agitation in dementia associated with Alzheimer’s disease. The company has also referenced additional pipeline candidates targeting Parkinson’s disease symptoms, pain, and metabolic conditions. Originally incorporated as India Globalization Capital, Inc., the company evolved from a diversified holdings and infrastructure-oriented business into a life sciences-focused enterprise and later rebranded as IGC Pharma, Inc. to reflect its biotechnology strategy.

Business Operations

IGC Pharma generates value primarily through research and development activities tied to its pharmaceutical pipeline. Its operations are centered on clinical-stage drug development, intellectual property creation, and related technology initiatives. The company’s pharmaceutical platform focuses on cannabinoid-derived formulations and combination therapies intended to address neuropsychiatric and neurodegenerative disorders. According to public disclosures, its operations include preclinical research, clinical trials, regulatory activities, and data-driven healthcare technologies supporting therapeutic development.

The company operates principally in the United States, while maintaining historical ties and certain operational relationships in India through earlier business activities and subsidiaries. IGC Pharma has controlled or referenced subsidiaries including IGC Pharma LLC and legacy operating entities connected to infrastructure and commodity businesses. The company has also disclosed collaborations with contract research organizations, clinical investigators, and technology partners supporting drug development and AI-assisted healthcare initiatives. Data regarding the scale of certain international operations is limited in current public disclosures, and some legacy business activities appear significantly reduced relative to the pharmaceutical segment.

Strategic Position & Investments

IGC Pharma’s strategic direction is centered on advancing proprietary therapeutics for Alzheimer’s disease and related neurological disorders. Its lead clinical initiative, IGC-AD1, has been positioned as a treatment candidate for agitation in dementia due to Alzheimer’s disease, an area with significant unmet medical need and growing commercial interest. The company has emphasized the use of cannabinoid science, formulation technologies, and AI-enabled patient analytics to differentiate its development platform. Public filings also indicate continued investment in intellectual property protection and clinical trial expansion.

In addition to its Alzheimer’s program, the company has disclosed development efforts involving metabolic disorders, pain management, and Parkinson’s-related conditions. IGC Pharma has referenced strategic investments in artificial intelligence tools intended to support clinical analysis and healthcare data applications. The company’s acquisition activity has been limited compared with larger pharmaceutical peers, and publicly available information does not indicate major transformative acquisitions in recent years. Data inconclusive based on available public sources regarding the long-term commercial scale of several non-core initiatives referenced in investor communications.

Geographic Footprint

IGC Pharma is headquartered in Potomac, Maryland, United States, and its primary operational and regulatory activities are concentrated in the United States. The company’s pharmaceutical development activities, investor engagement, and clinical strategy are largely aligned with the U.S. biotechnology and healthcare markets, including interactions with the U.S. Food and Drug Administration and domestic clinical research institutions.

Historically, the company maintained business exposure in India through infrastructure and commodity-related subsidiaries and commercial activities predating its pharmaceutical transition. Current public disclosures indicate a more limited international operational footprint compared with multinational pharmaceutical companies, though the company continues to reference international research relationships and global intellectual property considerations. Its market visibility is primarily within North America, with limited evidence of large-scale commercial operations across Europe, Asia-Pacific, or Latin America.

Leadership & Governance

IGC Pharma’s leadership team oversees a strategy focused on clinical-stage biotechnology development, cannabinoid-based therapeutics, and AI-supported healthcare technologies. The company’s governance structure follows the standards applicable to publicly traded U.S. companies, with oversight by a board of directors and executive leadership team. Corporate communications and SEC disclosures emphasize disciplined clinical advancement, intellectual property development, and expansion within neurodegenerative disease therapeutics.

Key executives identified in recent public filings and company disclosures include:

• Ram Mukunda – Chief Executive Officer
• Claudia Grimaldi – Chief Financial Officer
• Richard Prins – Chief Operating Officer
• Laurie Berman – Vice President of Clinical Development

Leadership communications have consistently emphasized long-term pharmaceutical development, advancement of Alzheimer’s-related clinical programs, and the integration of technology-driven healthcare analytics into the company’s operating model. Executive composition and titles may change over time based on subsequent company filings and governance updates.